Lamivudine News and Research

RSS
MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Clinton Foundation reaches deal with Matrix, Pfizer to cut prices for second-line Arvs, TB drug

Clinton Foundation reaches deal with Matrix, Pfizer to cut prices for second-line Arvs, TB drug

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

Antiretroviral therapy earlier yields better clinical outcomes

Antiretroviral therapy earlier yields better clinical outcomes

Research looks at the elimination of hepatitis B and C

Research looks at the elimination of hepatitis B and C

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

FDA grants tentative approval for 75th generic anti-retroviral drug

FDA grants tentative approval for 75th generic anti-retroviral drug

PEPFAR suspends funding for three Ranbaxy AIDS drugs banned by FDA

PEPFAR suspends funding for three Ranbaxy AIDS drugs banned by FDA

Thai health experts call for review of prevention of mother-to-child HIV transmission program

Thai health experts call for review of prevention of mother-to-child HIV transmission program

Canadian drug company awarded Rwandan contract to provide combination antiretroviral

Canadian drug company awarded Rwandan contract to provide combination antiretroviral

Apotex receives final tender approval from Rwanda for vital AIDS drug

Apotex receives final tender approval from Rwanda for vital AIDS drug

Clinton Foundation, UNITAID announce new antiretroviral discounts

Clinton Foundation, UNITAID announce new antiretroviral discounts

Monitoring AIDS treatment by physical symptoms is effective

Monitoring AIDS treatment by physical symptoms is effective

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

HIV drugs, Abacavir and Didanosine increase the risk of heart attack

HIV drugs, Abacavir and Didanosine increase the risk of heart attack

Entecavir can compromise HIV treatment

Entecavir can compromise HIV treatment

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Clinton to the rescue again!

Clinton to the rescue again!

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.